Hinova Pharmaceuticals (SHSE:688302) EPS (Basic): ¥-1.37 (TTM As of Mar. 2026)


SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
24 GF Score
Price ¥32.90
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals EPS (Basic)?

Hinova Pharmaceuticals SHSE:688302 -5.68% 24 EPS (Basic) is ¥-1.37 as of Mar. 2026. GuruFocus rates SHSE:688302 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Hinova Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ¥-0.30. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-1.37.

Hinova Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was ¥-0.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-1.37.

Hinova Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was ¥-0.31. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.38.

During the past 3 years, the average EPS without NRI Growth Rate was 20.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 23.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Hinova Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 24.70% per year. The lowest was 20.00% per year. And the median was 20.90% per year.

Hinova Pharmaceuticals  (SHSE:688302) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hinova Pharmaceuticals EPS (Basic) Related Terms

Hinova Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Hinova Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals EPS (Basic) Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -4.12 -3.32 -2.97 -2.01 -1.39

Hinova Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.30 -0.38 -0.39 -0.30
SHSE:688302
24GF Score
Hinova Pharmaceuticals Inc SHSE:688302
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hinova Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-137.253-0)/98.743
=-1.39

Hinova Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-29.882-0)/99.607
=-0.30

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-1.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ¥-1.37 mean?
Hinova Pharmaceuticals (SHSE:688302) has a EPS (Basic) of ¥-1.37 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hinova Pharmaceuticals and its competitors.
Is Hinova Pharmaceuticals' EPS (Basic) too high?
Hinova Pharmaceuticals' current EPS (Basic) is ¥-1.37. Overall, Hinova Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?
Hinova Pharmaceuticals' EPS (Basic) of ¥-1.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current EPS (Basic) is ¥-1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current EPS (Basic) of ¥-1.37. The current EPS (Basic) is ¥-1.37. Hinova Pharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current EPS (Basic) is ¥-1.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
24GF Score

Get the complete analysis for SHSE:688302

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥32.90
Price